Eva Martin, MD

Eva is the founder and CEO of Elm Tree Medical Inc., a medical device company focused on women’s health. Eva has an extensive background in women’s health and clinical research. She graduated cum laude from Harvard College, concentrating in Social and Cognitive Neurosciences with a Secondary Field in Studies in Women, Gender, and Sexuality. After graduation, Eva coordinated the Survivorship Program and related clinical trials for the University of California, San Francisco Breast Care Center. Eva earned her MD from Harvard Medical School, during which time she was heavily involved in clinical research at Brigham and Women’s Hospital, Boston Children’s Hospital, Beth Israel Deaconess Medical Center, and the University of California, San Francisco. Following medical school, Eva completed her internship training in OBGYN at Kaiser Permanente San Francisco. In June 2015, she founded Elm Tree Medical Inc. and currently works full time as Elm Tree Medical’s CEO.

Eva has volunteered in public hospitals and clinics in cities as diverse as Bucharest, Boston, and Cibecue. She currently volunteers as a Mentor for the Harvard Center for Public Interest Careers. She is passionate about health care innovation, especially in the field of women's health, and finding novel ways to enhance the health of local, national, and international communities. 


Andrew Perlman, MD, PhD

Andy is a leader in the fields of drug development and entrepreneurship. He serves as the Chief Advisor for Elm Tree Medical Inc. and a member of the Board of Directors.  His extensive experience includes serving as the Senior Director of Clinical Research at Genentech from 1988 to 1993. During this time, he led the development of human growth hormone and other endocrine drugs and drug candidates.  In 1993, he joined new drug discovery company Tularik as its Vice President and then Executive Vice President until 2004. Andy had a broad range of responsibilities at Tularik, from identification of promising new drugs to coordination of clinical trials to management of business and investor relations. Amgen acquired Tularik in 2004 for $1.3 billion.  Andy took a brief hiatus from Tularik for 9 months in 2002, when he served as the CEO of Affymax. After Tularik’s acquisition, Andy founded Innate Immune Inc., an early stage biotech company, and serves as its CEO. He is now also the Chief Medical Officer and Managing Director of Velocity Pharmaceutical Development, a pharmaceutical company focused on efficient development of attractive drug candidates.

Andy earned his BS from MIT and his MD and PhD from New York University, and completed his post-doctoral research in Nobel laureate Professor Eric Kandel’s laboratory. He completed his post-graduate clinical training at NYU and Stanford School of Medicine, where he served as an assistant professor from 1984 to 1987.

Andy has served as a consultant, advisor, and board member to many notable companies. He is also on the board of Ecumenical Hunger Project of East Palo Alto, CA.